# Senaparib (IMP4297)

Source: https://onco.cc/drugs/imp4927/  
OnCo record `imp4927` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Senaparib is an oral PARP inhibitor from IMPACT Therapeutics tested as maintenance treatment after first-line chemotherapy for advanced ovarian cancer. On 17 September 2026 the EMA's medicines committee recommended EU approval under the name Sepalna; the European Commission's decision is pending.

## Summary

Senaparib (IMP4297; the registry's spelling of the code is IMP4927) is a small-molecule PARP inhibitor developed by IMPACT Therapeutics. The phase 3 study NCT04169997 (FLAMES, 404 participants) tested it as monotherapy maintenance after first-line chemotherapy in advanced ovarian cancer. On 17 September 2026 the CHMP adopted a positive opinion recommending a marketing authorisation for Sepalna (applicant SFL Pharmaceuticals Deutschland GmbH) as monotherapy for the maintenance treatment of adults with advanced (FIGO stage III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response after first-line platinum-based chemotherapy. The register gives the benefit as longer progression-free survival than placebo and lists anaemia, leukopenia, neutropenia, thrombocytopenia, nausea, raised transaminases and fatigue first among the most common side effects. The status stays at phase 3 until the European Commission decides. No efficacy figures are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: senaparib; IMP4297; IMP4927; Sepalna
- Tags: pipeline; ctgov-ingest
- Brand: Sepalna
- Modality: small molecule (oral PARP inhibitor)
- Mechanism: Inhibitor of poly(ADP-ribose) polymerase (PARP), ATC code L01XK07, that blocks the repair of damaged DNA in cancer cells and causes them to die (EMA summary of opinion, 17 September 2026).

## Notes

- Mechanism, indication wording, applicant and opinion date read from the EMA register page for Sepalna on 24 September 2026 (PR 74 review); before that the record said the target was not stated.

## Sources

- ClinicalTrials.gov: trials of IMP4927: https://clinicaltrials.gov/search?intr=IMP4927
- Sponsor page: https://www.impacttherapeutics.com
- EMA: Sepalna (senaparib), CHMP opinion 17 September 2026: https://www.ema.europa.eu/en/medicines/human/EPAR/sepalna

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- targets: [PARP](https://onco.cc/targets/parp/)
- companies: [IMPACT Therapeutics](https://onco.cc/companies/impact-therapeutics/)
- trials: [A Study of IMP4297 as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer](https://onco.cc/trials/nct04169997/)

---
JSON: https://onco.cc/api/v1/entities/imp4927.json